Personalized combo therapy aims to outsmart Drug-Resistant lung cancer
NCT ID NCT07351565
First seen Jan 20, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This early-phase study tests whether adding the statin drug pitavastatin to standard chemotherapy can shrink tumors in people with advanced non-small cell lung cancer that no longer responds to second-line treatment. A lab test using the patient's own tumor cells will guide which chemotherapy drugs are used. The goal is to see if this personalized approach improves the tumor shrinkage rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.